Use: Labeled indications
- Renvela ® (sevelamer carbonate) is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Renvela ® (sevelamer carbonate) is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis. Renvela ® is a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis. (1)
Contraindications
- Bowel obstruction
- Hypersensitivity to sevelamer carbonate, sevelamer hydrochloride or excipients
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS Renvela is contraindicated in patients with bowel obstruction. Renvela is contraindicated in patients with known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients. Bowel obstruction. (4) Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients. (4)
Dosing: Adult
- Hyperphosphatemia in CKD on dialysis (adults, not on a binder): Serum phosphorus >5.5 to <7.5 mg/dL: 0.8 g three times daily with meals; ≥7.5 mg/dL: 1.6 g three times daily; titrate by 0.8 g per meal every 2 weeks
- Starting dose of Renvela is 0.8 or 1.6 grams administered orally three times per day with meals based on serum phosphorus levels for adult patients and based on body surface area (BSA) category for pediatric patients. (2.1)
- Titrate by 0.8 g per meal in two-week intervals for adult patients as needed to obtain serum phosphorus target. (2.1)
- Titrate based on BSA category for pediatric patients in two-week intervals for 6 weeks and then every 4 weeks as needed to obtain serum phosphorus target. (2.1)
2.1 General Dosing Information Starting Dose for Adult Patients Not Taking a Phosphate Binder
2.1 General Dosing Information Starting Dose for Adult Patients Not Taking a Phosphate Binder. The recommended starting dose of Renvela is 0.8 to 1.6 g taken orally with meals based on serum phosphorus level. Table 1 provides recommended starting doses of Renvela for adult patients not taking a phosphate binder. Table 1: Starting Dose for Adult Dialysis Patients Not Taking a Phosphate Binder Serum Phosphorus Renvela >5.5 and <7.5 mg/dL 0.8 g three times daily with meals ≥7.5 mg/dL 1.6 g three times daily with meals Dose Titration for Adult Patients Taking Renvela.
Titrate the Renvela dose by 0.8 g three times per day with meals at two-week intervals as necessary to achieve target serum phosphorus levels. Based on clinical studies, the average prescribed adult daily dose of sevelamer carbonate is approximately 7.2 g per day. The highest daily adult dose of sevelamer carbonate studied was 14 grams in CKD patients on dialysis.
Starting Dose for Pediatric Patients Not Taking a Phosphate Binder. The recommended starting dose for pediatric patients 6 years of age and older is 0.8 to 1.6 g taken three times per day with meals based on the patient's body surface area (BSA) category; see Table 2. Table 2: Recommended Starting Dosage and Titration Increment Based on Pediatric Patient's Body Surface Area (m 2) BSA (m 2) Starting Dose Per Meal/Snack Titration Increases/Decreases Per Dose ≥0.75 to <1.2 0.8 g Titrate by 0.4 g ≥1.2 1.6 g Titrate by 0.8 g Dose Titration for Pediatric Patients Taking Renvela.
Titrate the Renvela dose as needed to achieve target levels at two-week intervals based on BSA category, as shown in Table 2. Switching from Sevelamer Hydrochloride Tablets. For adult patients switching from sevelamer hydrochloride tablets to sevelamer carbonate tablets or powder, use the same dose in grams. Switching between Sevelamer Carbonate Tablets and Powder.
Use the same dose in grams. Switching from Calcium Acetate. Table 3 gives recommended starting doses of Renvela based on a patient's current calcium acetate dose. Table 3: Starting Dose for Dialysis Patients Switching from Calcium Acetate to Renvela Calcium Acetate 667 mg (Tablets per meal) Renvela 1 tablet 0.8 g 2 tablets 1.6 g 3 tablets 2.4 g
2.2 Sevelamer Carbonate Powder Preparation Instructions
2.2 Sevelamer Carbonate Powder Preparation Instructions Sevelamer carbonate powder is available in 0.8 or 2.4 g packets. For dose increments of 0.4 g, use one half of a 0.8 g packet. Place the sevelamer carbonate powder in a cup and suspend in the amount of water described in Table 4. Table 4: Sevelamer Carbonate Powder Preparation Instructions Amount of Renvela Powder Minimum Amount of Water for Dose Preparation (either ounces, mL, or tablespoon) Ounces mL Tablespoons 0.4 g 1 30 2 0.8 g 1 30 2 2.4 g 2 60 4 Instruct patients to stir the mixture vigorously (it does not dissolve), resuspend, if necessary, right before administration, and drink the entire preparation within 30 minutes.
As an alternative to water, the entire contents of the packet may be pre-mixed with a small amount of food or beverage and consumed immediately (within 30 minutes) as part of the meal. Do not heat Renvela powder (e.g., microwave) or add to heated foods or liquids.
Dosing: Altered kidney function
Sevelamer is a non-absorbed phosphate binder. The US label indication is control of serum phosphorus in chronic kidney disease (CKD) on dialysis; it acts in the gut, so no kidney-function dose adjustment applies.
Kidney function measure: Not applicable (not absorbed); indication is CKD on dialysis.
Show full dosing details
- eGFR ≥60
- No indication.
- eGFR 30–59
- Not within the US label indication (dialysis only). Specialist input.
- eGFR 15–29
- Not within the US label indication (dialysis only). KDIGO 2017 suggests lowering elevated phosphate toward normal in CKD G3a–G5 and restricting calcium-based binders; non-calcium binders such as sevelamer are used off-label. Specialist input.
- eGFR <15 (not on dialysis)
- Not within the US label indication (dialysis only). KDIGO 2017 suggests lowering elevated phosphate toward normal in CKD G3a–G5 and restricting calcium-based binders; non-calcium binders such as sevelamer are used off-label. Specialist input.
- Hemodialysis (intermittent)
- Not taking a binder: phosphorus >5.5 to <7.5 mg/dL, 0.8 g three times daily with meals; ≥7.5 mg/dL, 1.6 g three times daily. Titrate by 0.8 g per meal every 2 weeks. Average about 7.2 g/day; highest studied 14 g/day (label).
- Peritoneal dialysis
- Same dialysis dosing (label indication is CKD on dialysis).
- CRRT
- Not applicable.
- Dialyzable? Not applicable (not absorbed).
- Monitoring Serum phosphorus; GI adverse effects; bicarbonate (label). Follow KDIGO CKD-MBD guidance.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Not within the label indication (dialysis only).
- eGFR 30–59
- Not within the label indication (dialysis only).
- eGFR 15–29
- Not within the label indication (dialysis only).
- eGFR <15 (not on dialysis)
- Not within the label indication (dialysis only).
- Hemodialysis (intermittent)
- BSA-based dosing above (label).
- Peritoneal dialysis
- BSA-based dosing above (label).
- CRRT
- Not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Dosage and administration (renal excerpts) US FDA label
Table 1: Starting Dose for Adult Dialysis Patients Not Taking a Phosphate Binder Serum Phosphorus Renvela >5.5 and <7.5 mg/dL 0.8 g three times daily with meals ≥7.5 mg/dL 1.6 g three times daily with meals Dose Titration for Adult Patients Taking Renvela .
The highest daily adult dose of sevelamer carbonate studied was 14 grams in CKD patients on dialysis.
Table 3: Starting Dose for Dialysis Patients Switching from Calcium Acetate to Renvela Calcium Acetate 667 mg (Tablets per meal) Renvela 1 tablet 0.8 g 2 tablets 1.6 g 3 tablets 2.4 g 2.2 Sevelamer Carbonate Powder Preparation Instructions Sevelamer carbonate powder is available in 0.8 or 2.4 g packets.
Dosing: Pediatric
- Approved ages
- CKD on dialysis, 6 years and older; not studied under 6 years (label).
- Usual dose
- By body surface area (BSA): BSA ≥0.75 to <1.2 m2, start 0.8 g per meal/snack, titrate by 0.4 g; BSA ≥1.2 m2, start 1.6 g per meal/snack, titrate by 0.8 g. Titrate every 2 weeks for 6 weeks, then every 4 weeks (label).
- Maximum dose
- Label gives no pediatric maximum; highest adult dose studied is 14 g/day.
- Neonates
- Neonates: not studied (under 6 years).
Less effective in children with low baseline phosphorus (under 13 years and those not on dialysis) (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use The safety and efficacy of Renvela in lowering serum phosphorus levels was studied in patients 6 years of age and older with CKD. In this study, Renvela was apparently less effective in children with a low baseline serum phosphorus, which described children <13 years of age and children not on dialysis.
Given its mechanism of action, Renvela is expected to be effective in lowering serum phosphorus levels in pediatric patients with CKD. Most adverse events that were reported as related, or possibly related, to sevelamer carbonate were gastrointestinal in nature. No new risks or safety signals were identified with the use of sevelamer carbonate in the trial.
Renvela has not been studied in pediatric patients below 6 years of age.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of Renvela did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.
Administration
2.2 Sevelamer Carbonate Powder Preparation Instructions Sevelamer carbonate powder is available in 0.8 or 2.4 g packets. For dose increments of 0.4 g, use one half of a 0.8 g packet. Place the sevelamer carbonate powder in a cup and suspend in the amount of water described in Table 4. Table 4: Sevelamer Carbonate Powder Preparation Instructions Amount of Renvela Powder Minimum Amount of Water for Dose Preparation (either ounces, mL, or tablespoon) Ounces mL Tablespoons 0.4 g 1 30 2 0.8 g 1 30 2 2.4 g 2 60 4 Instruct patients to stir the mixture vigorously (it does not dissolve), resuspend, if necessary, right before administration, and drink the entire preparation within 30 minutes. As an alternative to water, the entire contents of the packet may be pre-mixed with a small amount of food or beverage and consumed immediately (within 30 minutes) as part of the meal. Do not heat Renvela powder (e.g., microwave) or add to heated foods or liquids.
US FDA labelDosage forms
Philippines
- Film-coated tablet: 400 mg, 800 mg
- Powder for oral suspension: 800 mg
- Tablet: 800 mg
Registered products in the Philippines
75 products registered with the Food and Drug Administration (FDA) Philippines list Sevelamer as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products75
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AevelaSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Dynasty PharmaceuticalsImporter: AMB HK Enterprises Inc. | DRP-10877-05 | Dec 10, 2031 | |
BersevelSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-14864 | Jan 25, 2029 | |
CavsamirSevelamer Carbonate | 800 mg Film-Coated TabletHDPE Bottle x 270's (Box of 270's) | RxVAT-exempt | Dr. Reddy's Laboratories LimitedIndia | Importer: Dr. Reddy's Laboratories Philippines, Inc. | DR-XY48557 | Jan 6, 2028 | |
CorvelamSevelamer Carbonate | 800 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 30s and 100's) | RxVAT-exempt | Pharose Remedies LimitedIndia | Corbridge Group Phils. Inc.Importer: Medethix, Inc. | DRP-9636 | Apr 21, 2031 | |
DephosSevelamer Hydrochloride | 400 mg Film Coated TabletAlu-PVC/PVDC Blister Pack x 12's (Box of 180's) | RxVAT-exempt | Aupa Biopharm Co., Ltd.Taiwan | CDM Marketing CenterTrader: Anxo Pharmaceutical Co., Ltd. | DR-XY48007 | May 18, 2027 | |
DyvelamerSevelamer carbonate | 800 mg Film-Coated TabletHDPE Plastic Bottle x 30’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Dynasty PharmaceuticalsImporter: Ambica International Corporation | DRP-12411-07 | Aug 3, 2027 | |
EuroservSevelamer carbonate | 800 mg Film Coated TabletAlu/Alu Blister Pack x 6's (Box of 12's) | RxVAT-exempt | The Acme Laboratories LimitedIndia | Euro Generics International Phils., Inc. | DR-XY49447 | Jul 11, 2030 | |
EuroservSevelamer carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 6's (Box of 12's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DRP-17874 | Jul 11, 2030 | |
FosbindSevelamer CarbonateBrand per distributor; the FDA record lists no brand. | 800 mg Film-Coated TabletHDPE Bottle x 30’s (Box of 1’s) | RxVAT-exempt | Nanjing Hencer Pharmaceutical Co., Ltd.China | Goodfellow Pharma Corporation | DRP-19166 | Nov 11, 2031 | |
FosfamerSevelamer carbonate | 800 mg Film-Coated TabletHDPE Plastic bottle x 30's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | One Pharma Marketing Inc.Importer: Ambica International Corporation | DRP-12411-05 | Aug 3, 2027 | |
FosfamerSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | One Pharma Marketing Inc.Importer: Ambica International Corporation | DRP-14864-01 | Jun 25, 2029 | |
K-Guard 800Sevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Globela Pharma Private LimitedIndia | FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc. | DRP-10877-01 | Dec 10, 2026 | |
KaycelSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | The Cathay Yss Distributors Co., Inc.Importer: AMB HK Enterprises Inc. | DRP-10877-03 | Dec 10, 2036 | |
KhrizvelaSevelamer carbonate | 800 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Samson Laboratories Pvt. Ltd.India | Khriz Pharma Trading Inc. | DRP-12678 | Sep 22, 2027 | |
KydrelisSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Vitalife Pharma & Medical Supply Inc.Importer: Ambica International Corporation | DRP-14864-10 | Jan 25, 2029 | |
Lamsev 800Sevelamer Carbonate | 800 mg Film-Coated TabletWhite Opaque High Density Polyethylene (HDPE) Container with white Polypropylene child resistant closure with CR Closure with induction-sealing wad (Bottle of 30's and 180's) | RxVAT-exempt | Aurobindo Pharma Limited Unit VIIIndia | AAA Pharma, Inc. | DR-XY49347 | Mar 11, 2030 | |
LophosSevelamer Carbonate | 800mg Film-Coated TabletWhite Opaque HDPE Bottle x 180's (Box of 180's) | RxVAT-exempt | Pharmathen International SAGreece | Philcare Pharma Inc. | DR-XY48154 | Jul 1, 2027 | |
NefralSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Bell-Kenz Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-10876 | Dec 10, 2031 | |
NephrozenSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Kodapharm Med Corp.Importer: Ambica International Corporation | DRP-14864-02 | Jan 25, 2029 | |
NephvelaSevelamer Carbonate | 800mg Film Coated TabletHDPE bottle with PP cap (Box of 180 tablets) | RxVAT-exempt | Synthon Hispania SLSpain | Macropharma Corporation | DR-XY47959 | Apr 22, 2027 | |
NoneSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Reta DrugImporter: Ambica International Corporation | DRP-14864-06 | Jan 25, 2029 | |
NoneSevelamer Carbonate | 800 mg Film-Coated TabletOpaque White HDPE Bottle with Child -Resistant PP Cap x 30’s and 270’s (Box of 30’s and Box of 270’s) | RxVAT-exempt | Aizant Drug Research Solutions Pvt. Ltd.India | Medethix, Inc. | DRP-18713 | Aug 25, 2031 | |
PerfosenSevelamer Carbonate | 800 mg Film Coated TabletAlu Alu Blister Pack X 10's (Box of 30's) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt) Ltd.Pakistan | Kaufmann Pharma IncImporter: Stangen Pharmaceuticals Philippines Inc | DRP-10356 | Sep 16, 2031 | |
Pholamer 800Sevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-19153 | Nov 10, 2031 | |
RegisevSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14864-05 | Jan 25, 2029 | |
Ren-VSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Pharma Hub CorporationImporter: Ambica International Corporation | DRP-14863-01 | Jan 25, 2029 | |
RenaphosSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Littman Drug CorporationImporter: AMB HK Enterprises Inc. | DRP-10877-02 | Dec 10, 2031 | |
RenvelaSevelamer Carbonate | 800 mg Powder for Oral SuspensionOpaque, Foil Lined, Child Resistant Sachet (Box of 90's) | RxVAT-exempt | Rovi Pharma Industrial Services, S.A.Spain | Sanofi-Aventis Philippines, Inc. | DR-XY45980 | Aug 14, 2027 | |
RenvelaSevelamer Carbonate | 800 mg TabletHDPE Bottle of 30's | RxVAT-exempt | Sanofi Winthrop Industrie Carbon Blanc.France | Importer: Sanofi-Aventis Philippines, Inc. | DRP-5212 | Jun 15, 2028 | |
RenvexSevelamer Carbonate | 800 mg Film-Coated TabletHDPE Bottle of 30's | RxVAT-exempt | Haimen Pharma Inc.China | Goodfellow Pharma Corporation | DR-XY47915 | Apr 11, 2027 | |
RevlomerSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Importer: AMB HK Enterprises Inc. | DRP-13798 | Apr 28, 2028 | |
RinoseverSevelamer carbonate | 800 mg Film-Coated TabletHDPE Plastic bottle x 30's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Rinon Care Pharma, Inc.Importer: Ambica International Corporation | DRP-12411-03 | Aug 3, 2027 | |
RinoseverSevelamer Carbonate | Film-Coated Tablet 800 mgAlu / Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Sai Parenterals Ltd.India | Rinon Care Pharma, Inc.Importer: Nelpa Lifesciences, Inc. | DRP-11355-03 | Jul 30, 2030 | |
SefosSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | ECE Pharmaceuticals, Inc.Importer: Nelpa Lifesciences, Inc . | DRP-11355-01 | Mar 3, 2027 | |
SefosSevelamer carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Nucare Labs LLPIndia | ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-15803 | Sep 13, 2029 | |
Selaglob 800Sevelamer (as Carbonate) | 800mg Film Coated TabletAlu/Alu blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-13610 | Mar 16, 2028 | |
Selaglob 800Sevelamer Carbonate | 800mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DR-XY48067 | May 30, 2027 | |
SelamerSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-14864-04 | Jan 25, 2029 | |
SelvenormSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-14863 | Jan 25, 2029 | |
Sev CSevelamer carbonate | 800 mg Film-Coated TabletHDPE Plastic bottle x 30's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-12411-06 | Aug 3, 2032 | |
SevaforSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Euroasia Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-14864-08 | Jan 25, 2029 | |
SevagenSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's [Box of 30's] | RxVAT-exempt | Sai Parenterals Ltd.#51 TSIIC Industrial Park Hyderabad - Warangal Highway Bhongir Telangana 508116 India | Ellebasy Medicale Group Inc.Importer: Nelpa Lifesciences, Inc. | DRP-11355-04 | Jul 30, 2030 | |
SevaparSevelamer Carbonate | 800 mg Film Coated TabletsAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises, Inc. | DRP-18361 | Jun 23, 2032 | |
SevecarboSevelamer carbonate | 800 mg Film-Coated tabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Samson Laboratories Pvt. Ltd.India | A. Pendragon International Distribution OpcImporter: Khriz Pharma Trading, Inc. | DRP-12678-01 | Sep 22, 2027 | |
SevelaSevelamer Carbonate | 800mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Chen Ho Pharmaceutical Co., Ltd. (Sinying Plant)Taiwan | Britton Distributions, Inc. | DR-XY48097 | Jun 8, 2027 | |
SevelabritSevelamer carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sai Parenterals Ltd.India | Britton Distributions, Inc.Importer: Nelpa Lifesciences, Inc. | DRP-11355-05 | Jul 30, 2030 | |
Sevelabrix 800Sevelamer carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-19151 | Nov 10, 2031 | |
SevelagetSevelamer carbonate | 800 mg Film-Coated TabletHDPE Plastic bottle x 30's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | 2MG IncorporatedImporter: Ambica International Corporation | DRP-12411-04 | Aug 3, 2027 | |
SevelaGetSevelamer carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | West Coast Pharmaceutical Works Ltd.India | Getmeds Philippines Inc.Importer: 2MG Incorporated | DRP-17743-01 | Feb 26, 2031 | |
SevelasanSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Bansan Pharma DistributorImporter: Ambica International Corporation | DRP-14864-03 | Jan 25, 2029 | |
SeveleraSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Ambica International Corporation | DRP-14864-09 | Jan 25, 2029 | |
Sevelex-800Sevelamer Carbonate | 800 mg Film-Coated TabletAlu/ Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Base Medico Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-18910 | Sep 29, 2031 | |
SevelifeSevelamer Carbonate | 800 mg Film Coated TabletAlu/alu blister pack of x 10's (Box of 30's) | RxVAT-exempt | Galen Pharmaceuticals LimitedIndia | Hira Pharmaceuticals Inc.Importer: Biophil Medical Equipment And Supplies Trading | DRP-18356 | Jun 18, 2031 | |
SevephosSevelamer carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Philrx Pharma Inc. | DRP-16551 | Apr 25, 2030 | |
SeverinSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Despina Pharma Inc. | DRP-16588 | May 8, 2030 | |
SeverqoSevelamer Carbonate | 800 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Pharose Remedies LimitedIndia | Ellebasy Medicale Group Inc.Importer: Medethix, Inc | DRP-9635-02 | Apr 21, 2031 | |
SevlafixxSevelamer carbonate | 800 mg Film-Coated TabletHDPE Plastic bottle x 30's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-12411-01 | Aug 3, 2027 | |
SevlarsaphSevelamer carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-11355 | Jul 30, 2030 | |
SevlorxSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-10877 | Dec 10, 2031 | |
SevrenSevelamer carbonate | 800 mg Film-Coated TabletOpaque White HDPE Bottle Sealed with Child- Resistant Closure Cap x 30's and 270's (Box of 30's and 270's) | RxVAT-exempt | Aizant Drug Research Solutions Pvt. Ltd.India | MedEthix, Inc. | DRP-17048 | Sep 12, 2030 | |
Sevrose-800Sevelamer Carbonate | 800 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Pharose Remedies LimitedIndia | Kaufmann Pharma Inc.Importer: Medethix, Inc. | DRP-9635 | Apr 21, 2031 | |
TrisevelSevelamer Carbonate | 800 mg Film-Coated TabletHDPE Bottle x 30's | RxVAT-exempt | Shandong Xinhua Pharmaceutical Co Limited (Plant 206XY)China | Triple Tact Import & Export Corp. | DRP-16840 | Jul 16, 2030 | |
UnbrandedSevelamer carbonate | 800 mg Film-Coated TabletHDPE bottle x 30's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-12411 | Aug 3, 2032 | |
UnbrandedSevelamer Carbonate | 800 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Pharose Remedies LimitedIndia | IE Medica, Inc.Importer: Medethix, Inc. | DRP-9635-01 | Apr 21, 2031 | |
UnbrandedSevelamer Carbonate | 800 mg Film-coated TabletAluminum Foil x 10's strip (Box of 100's) | RxVAT-exempt | Pharose Remedies LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-9636-01 | Apr 21, 2031 | |
VerlaservSevelamer carbonate | 800 mg Film-Coated TabletHDPE Plastic bottle x 30's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-12411-02 | Aug 3, 2027 | |
VerlaservSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Scriptmed, Inc.Importer: Ambica International Corporation | DRP-14863-02 | Jan 25, 2029 | |
VerseekSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medlink Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-14863-04 | Jan 25, 2029 | |
XelafosSevelamer carbonate | 800 mg Film-Coated TabletAlu/Alu blister pack x 10’s (Box of 30’s) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Helande Kidney Care Inc.Importer: Nelpa Lifesciences, Inc. | DRP-11355-02 | Mar 3, 2027 | |
XelafosSevelamer Carbonate | 800 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Pharose Remedies LimitedIndia | Helande Kidney Care Inc.Importer: Medethix, Inc. | DRP-9636-02 | Apr 21, 2031 | |
XeverixSevelamer carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc. | DRP-19150 | Nov 10, 2031 | |
ZevelatabSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14863-03 | Jan 25, 2029 | |
ZevemerrSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-14864-07 | Jan 25, 2029 | |
Zeveremz 800Sevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-19152 | Nov 10, 2031 | |
ZevlarSevelamer Carbonate | 800 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Lakeside Pharmaceuticals Phil., Inc.Importer: AMB HK Enterprises Inc. | DRP-10877-04 | Dec 10, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Tablets: 800 mg white oval, film-coated, compressed tablets, engraved with RV800 on one side Powder: 0.8 g and 2.4 g pale-yellow powder packaged in an opaque, foil-lined, heat-sealed packets Tablets: 800 mg (3) Powder: 0.8 g and 2.4 g packets (3)
Warnings/Precautions
Serious cases of dysphagia, bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery. (5.1)
5.1 Gastrointestinal Adverse Events
5.1 Gastrointestinal Adverse Events Patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders, including severe constipation, or major GI tract surgery were not included in the Renvela clinical studies. Cases of dysphagia and esophageal tablet retention have been reported in association with use of the tablet formulation of sevelamer, some requiring hospitalization and intervention.
Consider using sevelamer suspension in patients with a history of swallowing disorders. Cases of bowel obstruction, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, and perforation have also been reported with sevelamer use [see Adverse Reactions (6.2)]. Inflammatory disorders may resolve upon Renvela discontinuation.
Treatment with Renvela should be re-evaluated in patients who develop severe gastrointestinal symptoms.
5.2 Reductions in Vitamins D, E, K (clotting factors) and Folic Acid Levels
5.2 Reductions in Vitamins D, E, K (clotting factors) and Folic Acid Levels In preclinical studies in rats and dogs, sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, reduced vitamins D, E, and K (coagulation parameters) and folic acid levels at doses of 6–10 times the recommended human dose. In short-term clinical trials, there was no evidence of reduction in serum levels of vitamins.
However, in a one-year clinical trial, 25-hydroxyvitamin D (normal range 10 to 55 ng/mL) fell from 39 ± 22 ng/mL to 34 ± 22 ng/mL (p<0.01) with sevelamer hydrochloride treatment. Most (approximately 75%) patients in sevelamer hydrochloride clinical trials were receiving vitamin supplements.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Ciprofloxacin | Adjust or monitor | About 50% lower ciprofloxacin bioavailability. | Take ciprofloxacin at least 2 hours before or 6 hours after sevelamer. |
| Mycophenolate mofetil | Adjust or monitor | Lower mycophenolate exposure. | Take mycophenolate at least 2 hours before sevelamer. |
| Cyclosporine, tacrolimus, levothyroxine and other narrow-range oral drugs | Adjust or monitor | Possible lower absorption. | Separate dosing times; monitor levels or clinical response. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
7 DRUG INTERACTIONS There are no empirical data on avoiding drug interactions between Renvela and most concomitant oral drugs. For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [see Clinical Pharmacology (12.3)].
The duration of separation depends upon the absorption characteristics of the medication concomitantly administered, such as the time to reach peak systemic levels and whether the drug is an immediate-release or an extended-release product. Where possible consider monitoring clinical responses and/or blood levels of concomitant drugs that have a narrow therapeutic range.
Table 5: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from Renvela Dosing Recommendations Ciprofloxacin Take at least 2 hours before or 6 hours after sevelamer Mycophenolate mofetil Take at least 2 hours before sevelamer For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, consider separation of the timing of administration and/or monitor clinical responses or blood levels of the concomitant medication. (7) Sevelamer did not alter the pharmacokinetics of digoxin, enalapril, iron, metoprolol and warfarin.
(7) Sevelamer has demonstrated interaction with ciprofloxacin, mycophenolate mofetil, and therefore, these drugs should be dosed separately from Renvela. (7)
Adverse reactions
Common
- Vomiting (22%)
- Nausea (20%)
- Diarrhea (19%)
- Dyspepsia (16%)
- Abdominal pain (9%)
- Flatulence (8%)
- Constipation (8%) (sevelamer hydrochloride long-term studies)
Serious
- Dysphagia, bowel obstruction, perforation and other serious gastrointestinal events
- Lower vitamin D, E, K (clotting factors) and folic acid levels
- Peritonitis in peritoneal dialysis patients (8% in one 12-week study)
- Most of the safety experience is with sevelamer carbonate tablets and sevelamer hydrochloride. In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included: vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%), and constipation (8%). (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-847-0069 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. There are limited clinical trial data on the safety of Renvela.
However, because it contains the same active ingredient as the hydrochloride salt, the adverse event profiles of the two salts are expected to be similar. In a cross-over study in hemodialysis patients with treatment durations of eight weeks each and no washout, and another cross-over study in hemodialysis patients with treatment durations of four weeks each and no washout between treatment periods, the adverse reactions on sevelamer carbonate powder were similar to those reported for sevelamer hydrochloride.
In a parallel design study of sevelamer hydrochloride with treatment duration of 52 weeks, adverse reactions reported for sevelamer hydrochloride (n=99) were similar to those reported for the active-comparator group (n=101). Overall adverse reactions among those treated with sevelamer hydrochloride occurring in >5% of patients included: vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%), and constipation (8%).
A total of 27 patients treated with sevelamer and 10 patients treated with comparator withdrew from the study due to adverse reactions. Based on studies of 8–52 weeks, the most common reason for withdrawal from sevelamer hydrochloride was gastrointestinal adverse reactions (3%–16%). In 143 peritoneal dialysis patients studied for 12 weeks using sevelamer hydrochloride, most common adverse reactions were similar to adverse reactions observed in hemodialysis patients.
The most frequently occurring treatment emergent serious adverse reaction was peritonitis (8 reactions in 8 patients [8%] in the sevelamer group and 2 reactions in 2 patients [4%] on active control). Thirteen patients (14%) in the sevelamer group and 9 patients (20%) in the active-control group discontinued, mostly for gastrointestinal adverse reactions.
6.2 Postmarketing Experience
6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. The following adverse reactions have been identified during postapproval use of sevelamer hydrochloride or sevelamer carbonate: hypersensitivity, pruritus, rash, abdominal pain, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, fecal impaction, and uncommon cases of ileus, intestinal obstruction, and intestinal perforation.
Appropriate medical management should be given to patients who develop constipation or have worsening of existing constipation to avoid severe complications.
Monitoring parameters
- Serum phosphorus; GI adverse effects; bicarbonate (label). Follow KDIGO CKD-MBD guidance. Kidney
- Serum phosphorus during titration
- Vitamin D, E, K and folate status; clotting if on anticoagulants
- Swallowing problems and bowel symptoms
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Sevelamer carbonate is not absorbed systemically following oral administration and maternal use is not expected to result in fetal exposure to the drug. Clinical Considerations Sevelamer carbonate may decrease serum levels of fat-soluble vitamins and folic acid in pregnant women [see Clinical Pharmacology (12.2)].
Consider supplementation. Data Animal data In pregnant rats given dietary doses of 0.5, 1.5, or 4.5 g/kg/day of sevelamer hydrochloride during organogenesis, reduced or irregular ossification of fetal bones, probably due to a reduced absorption of fat-soluble vitamin D, occurred in mid and high-dose groups (human equivalent doses approximately equal to 3–4 times the maximum clinical trial dose of 13 g).
In pregnant rabbits given oral doses of 100, 500, or 1000 mg/kg/day of sevelamer hydrochloride by gavage during organogenesis, an increase of early resorptions occurred in the high-dose group (human equivalent dose twice the maximum clinical trial dose).
Mechanism of action
12.1 Mechanism of Action Renvela contains sevelamer carbonate, a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum (serum phosphorus).
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics In addition to effects on serum phosphorus levels, sevelamer hydrochloride has been shown to bind bile acids in vitro and in vivo in experimental animal models. Because sevelamer binds bile acids, it may interfere with normal fat absorption and thus may reduce absorption of fat-soluble vitamins such as A, D and K. In clinical trials of sevelamer hydrochloride, both the mean total and LDL cholesterol declined by 15%–31%; the clinical significance of this finding, which was observed after 2 weeks, is unclear. Triglycerides, HDL cholesterol, and albumin did not change.
Pharmacokinetics
Key PK parameters
| Bioavailability | Not systemically absorbed |
|---|---|
| Half-life in kidney failure (ESKD) kidney | Not applicable (not absorbed) |
| Metabolism (CYP, transporters) | Not absorbed |
| Active metabolites | None |
| Renal excretion kidney | 0% (not absorbed) |
| Dialyzability kidney | Not applicable (not absorbed). |
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics A mass balance study using 14 C-sevelamer hydrochloride, in 16 healthy male and female volunteers showed that sevelamer hydrochloride is not systemically absorbed. No absorption studies have been performed in patients with renal disease. Drug Interactions In vivo Sevelamer carbonate has been studied in human drug-drug interaction studies (9.6 grams once daily with a meal) with warfarin and digoxin.
Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been studied in human drug-drug interaction studies (2.4–2.8 grams single dose or three times daily with meals or two times daily without meals) with ciprofloxacin, digoxin, enalapril, iron, metoprolol, mycophenolate mofetil, and warfarin. Coadministered single dose of 2.8 grams of sevelamer hydrochloride in fasted state decreased the bioavailability of ciprofloxacin by approximately 50% in healthy subjects.
Concomitant administration of sevelamer and mycophenolate mofetil in adult and pediatric patients decreased the mean MPA C max and AUC 0–12h by 36% and 26%, respectively. Sevelamer carbonate or sevelamer hydrochloride did not alter the pharmacokinetics of enalapril, digoxin, iron, metoprolol, and warfarin when coadministered.
During postmarketing experience, cases of increased thyroid stimulating hormone (TSH) levels have been reported in patients coadministered sevelamer hydrochloride and levothyroxine. Reduction in concentrations of cyclosporine and tacrolimus leading to dose increases has also been reported in transplant patients when coadministered with sevelamer hydrochloride without any clinical consequences (for example, graft rejection).
The possibility of an interaction cannot be excluded with these drugs.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Sevelemer 800 mg film-coated tablet | ₱34.63 | per tablet | DPRI reference price |
Reference price based on the Maximum Wholesale Price (MWP); excluded from the 10% inflation allowance
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Sevelamer carbonate |
| PNF listing | Oral: 800 mg tablet |
| PNF listing | Oral: 800 mg powder for suspension |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Renvela · Genzyme Corporation [US FDA-approved label, version 47, November 25, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6328460-a57b-450b-a48c-6dcd4b476360
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Genzyme Corporation. (2025). Renvela (sevelamer carbonate) [Prescribing information; US FDA-approved label, NDA022318, set ID e6328460-a57b-450b-a48c-6dcd4b476360, version effective November 25, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6328460-a57b-450b-a48c-6dcd4b476360
- Ketteler, M., Block, G. A., Evenepoel, P., Fukagawa, M., Herzog, C. A., McCann, L., Moe, S. M., Shroff, R., Tonelli, M. A., Toussaint, N. D., Vervloet, M. G., & Leonard, M. B. (2017). Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: What's changed and why it matters. Kidney International, 92(1), 26–36. https://doi.org/10.1016/j.kint.2017.04.006
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .



